Sign In
Buy LUCD
$1.01
-0.0250 (-2.43%)
At Close: Jun 03, 2026
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters
08:01am, Thursday, 19'th Dec 2024
Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lu
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
08:01am, Wednesday, 11'th Dec 2024
Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing NEW
New convertible debt financing with existing long-term equity shareholders yields ~$18M in net cash proceeds after paying off existing convertible debt NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Lucid D
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
07:56am, Wednesday, 20'th Nov 2024
NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
08:15am, Monday, 18'th Nov 2024
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVme
Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript
02:44pm, Wednesday, 13'th Nov 2024
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Matt Riley - Director-Investor Relations Lishan Aklog - Chairman & Chief Execut
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results
08:01am, Wednesday, 13'th Nov 2024
EsoGuard® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term revenue
Publication, which once again demonstrates strong EsoGuard performance in a screening population, completes Lucid's clinical evidence package for submission to formally seek Medicare coverage NEW YORK
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
08:01am, Tuesday, 05'th Nov 2024
Industry veterans from leading cancer detection firm join Lucid to support expansion in fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets NEW YORK
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
08:31am, Wednesday, 30'th Oct 2024
Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , Oct. 30, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention me
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
07:51am, Tuesday, 15'th Oct 2024
Patent covers proprietary method using methylation of the CCNA1 gene to help detect esophageal precancer and cancer NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks
01:46pm, Wednesday, 09'th Oct 2024
Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Re
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
08:01am, Wednesday, 09'th Oct 2024
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
07:49am, Tuesday, 08'th Oct 2024
Company to showcase EsoGuard® and EsoCheck® at the conference's Innovation Pavilion NEW YORK , Oct. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a com
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks
09:27am, Friday, 04'th Oct 2024
Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Re
